Skip to main content

Christopher Lee Holley

Associate Professor of Medicine
Medicine, Cardiology
DUMC Box 2647, 2301 Erwin Road, Durham, NC 27710
203 Research Drive, MSRB1 Rm 321, Durham, NC 27710

Research Interests


snoRNAs, RNA modifications, RNA therapeutics, PGD (primary graft dysfunction), AMR (antibody-mediated rejection)

Selected Grants


IND-enabling studies for an RNA therapeutic to treat atherosclerosis

ResearchPrincipal Investigator · Awarded by Department of Defense · 2024 - 2028

Medical Scientist Training Program

Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of General Medical Sciences · 2022 - 2027

A High-Throughput Screening Platform to Discover RNA Methylation Inhibitors

ResearchCollaborating Investigator · Awarded by National Cancer Institute · 2023 - 2026

Targeting snoRNAs to Treat Atherosclerosis

ResearchPrincipal Investigator · Awarded by UH Harrington Discovery Institute · 2024 - 2026

Mechanisms by which Small Nucleolar RNAs Exacerbate Atherosclerosis

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2022 - 2026

Cell and Molecular Biology Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2021 - 2026

Hematology & Transfusion Medicine (T32)

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026

Clinical and Therapeutic Implications of the Small Nucleolar RNA Snord67 in Breast Cancer Lymphatic Metastasis

ResearchMentor · Awarded by American Society of Clinical Oncology · 2024 - 2025

Defining Novel Roles of Ubiquitin Accumulation During the Mammalian Oxidative Stress Response

FellowshipCo-Sponsor · Awarded by National Institute of Environmental Health Sciences · 2022 - 2025

Role of RNA modifications in heart failure

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2025

SnoRNA-guided modifications of mRNA

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2024

Mechanistic Insights into m6A-Mediated Regulation of Brain Development

ResearchCollaborating Investigator · Awarded by National Institutes of Health · 2018 - 2024

Silencing small nucleolar RNAs with antisense oligonucleotides for treatment of atherosclerosis

ResearchPrincipal Investigator · Awarded by North Carolina Biotechnology Center · 2022 - 2024

Multidisciplinary Heart and Vascular Diseases

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1975 - 2023

Epitranscriptomic modification of HIV-1 transcripts: Effects of drugs of abuse

ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2023

Medical Scientist Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1997 - 2022

Structural studies of post-transcriptionally modified snRNAs and their role in congenital heart disease

FellowshipCo-Sponsor · Awarded by National Institutes of Health · 2020 - 2022

Increasing the Diagnostic Accuracy of Antibody Mediated

Clinical TrialPrincipal Investigator · Awarded by CareDx, Inc. · 2020 - 2021

Mass Spectrometric Screening of the Effect of Chemical Toxicants on the Human Epitranscriptome during Stem Cell Differentiation

ResearchPrincipal Investigator · Awarded by Athghin Biotechnology, Inc · 2017 - 2018

Role of snoRNAs in regulation of cardiac hypertrophy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2018

Regulation of oxidative stress and reactive oxygen species (ROS) in heart failure.

ResearchPrincipal Investigator · Awarded by American Heart Association · 2016 - 2017

SNORNAS ARE ESSENTIAL MEDIATORS OF ROS SIGNALING IN CARDIOVASCULAR CELLS

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2017

Bioactive sphingolipid signaling in cardiomyocyte mitophagy

FellowshipPrincipal Investigator · Awarded by American Heart Association · 2016 - 2016

External Relationships


  • Novo Nordisk
  • OneFul Health
  • snoPanTher

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.